Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma ...
Participants received CD68-ET3-LV–transduced autologous CD34+ HSCs at doses of 5.0×10 6 to 6.1×10 6 per kilogram of body weight. The vector copy numbers in the final drug product were 1.0 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback